Literature DB >> 9928246

Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists.

K A Berg1, S Maayani, J Goldfarb, W P Clarke.   

Abstract

There is now considerable evidence that a single receptor subtype can couple to multiple effector pathways within a cell. Recently, Kenakin proposed a new concept, termed "agonist-directed trafficking of receptor stimulus", that suggests that agonists may be able to selectively activate a subset of multiple signaling pathways coupled to a single receptor subtype. 5-HT2A and 5-HT2C receptors couple to phospholipase C-(PLC) mediated inositol phosphate (IP) accumulation and PLA2-mediated arachidonic acid (AA) release. Relative efficacies of agonists (referenced to 5-HT) differed depending upon whether IP accumulation or AA release was measured. For the 5-HT2C receptor system, some agonists (e.g. TFMPP) preferentially activated the PLC-IP pathway, whereas others (e.g. LSD) favored PLA2-AA. As expected, EC50's of agonists did not differ between pathways. For the 5-HT2A receptor system, all agonists tested had greater relative efficacy for PLA2-AA than for PLC-IP. In contrast, relative efficacies were not different for 5-HT2A agonists when sequential effects in a pathway were measured (IP accumulation vs. calcium mobilization). These data strongly support the agonist-directed trafficking hypothesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9928246     DOI: 10.1111/j.1749-6632.1998.tb10180.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  21 in total

1.  Comparison of functional profiles at human recombinant somatostatin sst2 receptor: simultaneous determination of intracellular Ca2+ and luciferase expression in CHO-K1 cells.

Authors:  Caroline Nunn; Davide Cervia; Daniel Langenegger; Laurent Tenaillon; Rochdi Bouhelal; Daniel Hoyer
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

Review 2.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

Review 3.  Insights into the regulation of 5-HT2A serotonin receptors by scaffolding proteins and kinases.

Authors:  John A Allen; Prem N Yadav; Bryan L Roth
Journal:  Neuropharmacology       Date:  2008-07-02       Impact factor: 5.250

4.  MDMA-induced loss of parvalbumin interneurons within the dentate gyrus is mediated by 5HT2A and NMDA receptors.

Authors:  Stuart A Collins; Gary A Gudelsky; Bryan K Yamamoto
Journal:  Eur J Pharmacol       Date:  2015-04-30       Impact factor: 4.432

5.  Genetic deletion of p90 ribosomal S6 kinase 2 alters patterns of 5-hydroxytryptamine 2A serotonin receptor functional selectivity.

Authors:  Ryan T Strachan; Noah Sciaky; Mark R Cronan; Wesley K Kroeze; Bryan L Roth
Journal:  Mol Pharmacol       Date:  2009-11-20       Impact factor: 4.436

6.  Atypical antipsychotics and inverse agonism at 5-HT2 receptors.

Authors:  Laura C Sullivan; William P Clarke; Kelly A Berg
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

7.  Biased signaling at chemokine receptors.

Authors:  Jenny Corbisier; Céline Galès; Alexandre Huszagh; Marc Parmentier; Jean-Yves Springael
Journal:  J Biol Chem       Date:  2015-01-22       Impact factor: 5.157

Review 8.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

9.  5-HT2A/2C receptor signaling via phospholipase A2 and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter.

Authors:  Ying Qu; Nelly Villacreses; Dennis L Murphy; Stanley I Rapoport
Journal:  Psychopharmacology (Berl)       Date:  2005-04-15       Impact factor: 4.530

10.  Imaging elevated brain arachidonic acid signaling in unanesthetized serotonin transporter (5-HTT)-deficient mice.

Authors:  Mireille Basselin; Meredith A Fox; Lisa Chang; Jane M Bell; Dede Greenstein; Mei Chen; Dennis L Murphy; Stanley I Rapoport
Journal:  Neuropsychopharmacology       Date:  2009-01-14       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.